Cosmos Health Inc.報告了強大的第一季度2025年表演

股東的股權增加了142萬美元，而負債比率的比率仍然是54.6％，這反映了持續的金融紀律。

Cosmos Health, Inc. (Nasdaq: COSM) today announced its financial results for the first quarter of 2025.

Cosmos Health，Inc。 （NASDAQ：COSM）今天宣布了2025年第一季度的財務業績。

For the quarter, the company reported a net loss of $0.19 million, or $0.01 loss per share, on adjusted net income. This compares to adjusted net income of $3.41 million, or $0.18 earnings per share, in the prior-year period. The company also reported adjusted EBITDA of $0.1 million, compared to adjusted EBITDA of $3.3 million in the prior-year quarter.

該季度的淨虧損為淨收入，淨虧損為1990萬美元，每股0.01美元。相比之下，在上年期間，調整後的淨收入為341萬美元，每股收益0.18美元。該公司還報告了調整後的EBITDA為100萬美元，而在上一年的調整後的EBITDA為330萬美元。

"We are pleased with our strong first-quarter performance and the steady progress across multiple strategic areas," said Greg Siokas, CEO of Cosmos Health. "Gross profit and gross margins increased significantly, supported by an improved product mix and stronger operating leverage. Our continued focus on efficiency and disciplined cost management is yielding tangible results, as reflected in our return to profitability on both an Adjusted EBITDA and Adjusted Net Income basis."

Cosmos Health首席執行官Greg Siokas說：“我們對我們在多個戰略領域的出色表現以及在多個戰略領域的穩定進步感到滿意。” “毛利潤和毛利率大大提高，得到了改進的產品組合和更強的運營槓桿的支持。我們繼續關注效率和紀律處分的成本管理正在產生切實的結果，這反映在我們以調整後的EBITDA和調整後的淨收入基礎上恢復盈利能力。”

The company's stock price increased by 5.3% to $57.2 million as of March 31, 2025, from $54.3 million as of December 31, 2024. The increase in stockholders' equity was due to several factors, including the company's focus on reducing liabilities-to-assets ratio, which remained a modest 54.6%.

截至2025年3月31日，該公司的股票價格從截至2024年12月31日的5430萬美元上漲，至5720萬美元，截至2024年3月31日，股東權益的增加是由於多個因素，包括該公司對減少負債債務比率的關注，這仍然是54.6％。

"Despite the challenging macroeconomic environment, we continue to execute on our key priorities and deliver solid financial performance," said Siokas. "We are confident in our ability to drive further growth and value creation for our shareholders in the quarters to come."

Siokas說：“儘管宏觀經濟環境充滿挑戰，但我們仍在繼續執行我們的關鍵優先事項並提供穩固的財務績效。” “我們對我們在未來季度推動股東進一步增長和價值創造的能力充滿信心。”

The company also announced that it has entered into an agreement to provide a portion of its preferred stock to a strategic investor in exchange for a minimum investment of $20 million in Cosmos’ common stock over a period of 12 months following the closing of the preferred stock purchase agreement. The strategic investor will also become a member of Cosmos' Board of Directors.

該公司還宣布已簽訂協議，向戰略投資者提供一部分優先股，以換取在截止優先股票購買協議後12個月內的最低投資Cosmos的普通股。戰略投資者還將成為Cosmos董事會成員。

"This partnership marks a significant milestone for Cosmos as we navigate the final stage of our journey to profitability and expand our footprint in the global health and wellness market," said Siokas. "We are grateful for the trust and confidence shown by this investor, and we believe this collaboration will be instrumental in driving Cosmos's long-term success."

Siokas說：“這種夥伴關係標誌著宇宙的重要里程碑，因為我們在盈利能力旅程的最後階段並擴大了我們在全球健康和保健市場的足跡。” “我們感謝這位投資者所表現出的信任和信心，我們認為這項合作將有助於推動Cosmos的長期成功。”

Cosmos Health is a diversified, vertically integrated global health group, founded in 1990 and based in Greece with a subsidiary in the U.S., operating in accordance with European and U.S. regulations. The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices in accordance with European GMP, and distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the U.K.

Cosmos Health是一個多元化的，垂直整合的全球衛生小組，成立於1990年，並根據歐洲和美國法規運作，並與美國的一家子公司建立在希臘。該公司擁有專有藥品和營養品牌的組合，製造藥品，食品補充劑，化妝品，生物劑和醫療設備，按照歐洲GMP的規定，並分佈了一系列藥品，包括通過品牌的普通藥物，以及既有品牌的藥物，以及既有品牌的藥物，又包括在內 英國

Cosmos’ products are sold in a wide range of channels, including food retailers, convenience stores, pharmacies, e-commerce platforms and social media channels. The company's products are available in several major markets worldwide, including Greece, Cyprus, Israel, Bulgaria, Romania, Turkey, Egypt, the U.K., Germany, France, Spain, Italy, Benelux, Scandinavia, the Baltic States, the Middle East, and North America, through partnerships with local distributors.

Cosmos的產品以各種渠道出售，包括食品零售商，便利店，藥房，電子商務平台和社交媒體渠道。該公司的產品可在全球幾個主要市場上購買，包括希臘，塞浦路斯，以色列，保加利亞，羅馬尼亞，土耳其，埃及，英國，德國，法國，西班牙，意大利，意大利，斯堪的納維亞半島，巴西亞維亞，巴西尼亞省，巴羅的海州，中東，中東和北美，通過與當地分銷商的合作。

The company is expanding its product portfolio with a focus on R&D partnerships targeting major health disorders such as obesity, diabetes and cancer, enhanced by artificial intelligence drug repurposing technologies, and developing novel patented nutraceuticals, specialized root extracts, proprietary complex generics and innovative OTC products.

該公司正在擴大其產品組合，重點是針對肥胖，糖尿病和癌症等重大健康疾病的研發夥伴關係，並通過人工智能藥物重新利用技術增強，並開發了新穎的專利營養營養素，專業的根源提取物，專有的複雜的複雜通用通用性通用和創新的OTC產品。

Cosmos is also entering the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, U.S., and is integrating this technology to provide patients with seamless access to medical care.

Cosmos還通過收購位於美國德克薩斯州的Zipdoctor，Inc。進入遠程醫療空間，並將這項技術整合為為患者提供無縫獲得醫療服務的機會。

The company is expanding throughout Europe, Asia and North America, with offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, U.K.

該公司在整個歐洲，亞洲和北美都在擴張，在塞薩洛尼基和雅典，希臘以及英國哈洛的辦公室和分銷中心

Cosmos Health is publicly traded on Nasdaq under the symbol COSM. The company is included in the Nasdaq Small Cap Index and the Global Health Technology Index.

Cosmos Health在符號COSM下在納斯達克公開交易。該公司被包括在納斯達克小型CAP指數和全球衛生技術指數中。